Amino Acid Sequence Disclosed In Whole Or In Part; Or Conjugate, Complex, Or Fusion Protein Or Fusion Polypeptide Including The Same Patents (Class 424/185.1)
  • Patent number: 10973893
    Abstract: The present invention provides a universal, yet adaptable, anti-tag chimeric antigen receptor (AT-CAR) system which provides T cells with the ability and specificity to recognize and kill target cells, such as tumor cells, that have been marked by tagged antibodies. As an example, ?FITC-CAR-expressing T cells have been developed that specifically recognize various human cancer cells when those cells are bound by cancer-reactive FITC-labeled antibodies. The activation of ?FITC-CAR-expressing T cells is shown to induce efficient target lysis, T cell proliferation, and cytokine/chemokine production. The system can be used to treating subjects having cancer.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: April 13, 2021
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Eduardo Davila, Koji Tamada
  • Patent number: 10968269
    Abstract: Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC molecules containing one or more Borrelia derived peptides are disclosed. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis. The invention generally relates to the sample-mounted use of MHC complexes and MHC multimers. Also comprised by the invention is the field of therapy and vaccine, including therapeutic/vaccine methods and therapeutic/vaccine compositions.
    Type: Grant
    Filed: December 30, 2008
    Date of Patent: April 6, 2021
    Assignee: Agilent Technologies, Inc.
    Inventors: Jørgen Schøller, Liselotte Brix, Henrik Pedersen
  • Patent number: 10967015
    Abstract: A method for treating a tumor by administering to a subject in need of such treatment an effective amount for treating the tumor of a Poxviridae decapping deficient mutant virus. Also disclosed are mutant Poxviridae and pharmaceutical formulations for use in the method.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: April 6, 2021
    Assignee: New York University
    Inventor: Ian J Mohr
  • Patent number: 10947297
    Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: March 16, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
  • Patent number: 10947278
    Abstract: Provided is a recombinant vector including a porcine Fc fragment. By fusing the porcine Fc fragment with various target proteins by using the recombinant vector of the present invention, not only target proteins may be expressed using various hosts including plants, but the productivity and stability of target proteins may also be increased.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: March 16, 2021
    Assignee: BIOAPPLICATIONS INC.
    Inventor: Yongjik Lee
  • Patent number: 10945962
    Abstract: Controlled-release formulations of carboxy-terminal C5a analogs (such as sustained-release formulations of the analogs), and their use in methods for treating and preventing an infection or a disease such as cancer, for directly killing microorganisms, for vaccine preparation, for inducing an immune response and for targeting antigen-presenting cells and other cells bearing a C5a receptor, are provided.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: March 16, 2021
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
    Inventors: Joseph A. Vetro, Sam D. Sanderson
  • Patent number: 10933118
    Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: March 2, 2021
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Patent number: 10927188
    Abstract: Provided is a method for producing a short-chain peptide-immobilized carrier that maintains a secondary structure of a short-chain peptide, the method including a step of preparing an alcohol solution containing an alcohol solvent, and a short-chain peptide having a plurality of immobilizing functional groups, the short-chain peptide having a secondary structure induced in the alcohol solvent; and a step of bringing a carrier coupled with a spacer having a reactive group that reacts with the immobilizing functional group, into contact with the alcohol solution, and thereby immobilizing the short-chain peptide to the spacer.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: February 23, 2021
    Assignee: FUJIFILM Corporation
    Inventor: Koichi Minami
  • Patent number: 10927161
    Abstract: The present disclosure provides methods of modulating an immune response in an individual. The present disclosure provides methods of treatment. The present disclosure provides methods comprising administering a multimeric polypeptide (synTac) and an immune checkpoint inhibitor to an individual. The present disclosure provides methods comprising administering a multimeric polypeptide (synTac) to an individual who is undergoing treatment with immune checkpoint inhibitor.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: February 23, 2021
    Assignee: Cue Biopharma, Inc.
    Inventors: Ronald D. Seidel, III, Rodolfo J. Chaparro
  • Patent number: 10925902
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: February 23, 2021
    Assignee: VOR BIOPHARMA, INC
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Patent number: 10927143
    Abstract: The invention relates to a process for decontaminating a biological material by partitioning and inactivation techniques. The process includes the formation of a three-layer liquid system (a-b-c), where the layers are placed one onto the other and are different from each other in density and/or miscibility properties. The upper layer (a) has an aqueous solution of the biological material to decontaminate; the lower layer (c) has the solution inactivating viruses, prions or bacteria; the intermediate layer (b), interposed between the upper and lower layers, separates and protects the biological material from the inactivating solution which has an organic solvent or a mixture of more such solvents, immiscible at least with the upper layer. Moreover, the invention provides specific indications about the density difference between the layers in order to preserve system stability and, at the same time, protect the efficiency of decontamination and the biological activity of the material undergoing decontamination.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: February 23, 2021
    Assignee: ALTERGON S.A.
    Inventors: Costantino Cozzari, Luca Angiolini
  • Patent number: 10905741
    Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: February 2, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Patent number: 10898546
    Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: January 26, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Patent number: 10889638
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: January 12, 2021
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin Barbour, Philip James Dolan, III, Yue Liu, Svetlana Alexander, Mark E. Renz
  • Patent number: 10882894
    Abstract: The present invention provides peptidic TGF-? antagonists capable of inhibiting TGF-? signaling and disrupting the biochemical events that promote fibrosis and the epithelial-mesenchymal transition. The peptidic TGF-? antagonist may contain from 11 to 28 amino acid residues (for instance, may consist of from 12 to 16 amino acid residues) and may have the following structure (II): NH2? ETWIWLDTNMG-Xaa1-Y?COOH (II) wherein Xaa1 is any amino acid and Y is a peptide having from 0 to 9 amino acids. The peptidic TGF-? antagonists can advantageously be used for the prevention, treatment, and/or alleviation of the symptoms of a condition associated with an increase in TGF-? activity, including fibrosis (such as fibrosis of the skin, liver, lungs, and heart, among others) and cancer (including various carcinomas, such as squamous cell carcinoma, sarcomas, and metastatic cancers).
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: January 5, 2021
    Inventor: Anie Philip
  • Patent number: 10864262
    Abstract: Gram-negative bacterial strains are generated by inactivating at least one LytM catalytic domain-containing protein, such as NT013, NT017 and NT022 of non typeable H influenzae. The vesicles from these strains are useful for vaccination.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: December 15, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Maria Arico, Giuseppe Ercoli, Nathalie Norais, Marco Soriani, Chiara Tani
  • Patent number: 10858675
    Abstract: The present invention relates to a recombinant microorganism capable of producing 2,4-dihydroxybutyrate, which is characterized by an increased cellular export, and preferably by a decreased cellular import, of said 2,4 DHB. The invention also relates to a method for the optimized production of 2,4-dihydroxybutyrate by culturing said microorganism in a fermentation medium and recovering 2,4-DHB from said medium.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: December 8, 2020
    Assignee: METABOLIC EXPLORER
    Inventors: Wanda Dischert, Laurence Dumon-Seignovert, Perrine Vasseur, Gwénaëlle Bestel-Corre, Philippe Soucaille
  • Patent number: 10829538
    Abstract: The invention provides compositions, methods, and vaccines that may stimulate the immune system and that may be used for treating malignancies associated with overexpression of the HER3 protein. Such compositions include epitopes of the HER3 protein.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: November 10, 2020
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Brian J. Czerniecki, Gary K. Koski
  • Patent number: 10829752
    Abstract: Disclosed are bacterial toxins and uses thereof as specific proteases for Ras sarcoma oncoproteins (Ras proteins). The bacterial toxins may be modified for use as pharmaceutical agents for treating Ras-dependent diseases and disorders including cell proliferation diseases and disorders such as cancer.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: November 10, 2020
    Assignee: Northwestern University
    Inventors: Karla J. F. Satchell, Irena Antic, Marco Biancucci
  • Patent number: 10821151
    Abstract: The methods and compounds disclosed herein are useful in treating a subject having cancer or a viral infection by modulating the innate and adaptive immune systems typically by both inhibiting the function of inhibitory receptors and enhancing activity of activating receptors. Preferred therapeutic compositions comprise a carrier; at least one agent selected from the group consisting of: an anti-inflammatory agent, a cytotoxic T cell proliferation agent, or a NK cell proliferation agent; and a therapeutic peptide of the invention. In certain embodiments the compositions further include a second therapeutic peptide and/or an immunoglobulin admixed therewith in an amount sufficient to enhance passive immunoprotection in the subject.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: November 3, 2020
    Assignee: Susavion Biosciences, Inc.
    Inventors: Laura L. Eggink, J. Kenneth Hoober
  • Patent number: 10816554
    Abstract: Compositions and methods are provided for the identification of peptide sequences that are ligands for a T cell receptor (TCR) of interest, in a given MHC context.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: October 27, 2020
    Assignees: The Board of Trustees of the Leland Stanford Junior University, California Institute of Technology
    Inventors: Michael Edward Birnbaum, Juan Luis Mendoza, Michael Thomas Bethune, David Baltimore, Kenan Christopher Garcia
  • Patent number: 10799573
    Abstract: Bordetella pertussis iron receptor proteins or portions thereof (e.g., one or more extracellular domains), alone or spliced into B. pertussis scaffold proteins (e.g., fimbrial or flagellin), are provided and can be used in acellular vaccines to protect against pertussis or other Bordetella diseases in humans and non-human mammals. In addition, Bordetella species grown under iron-starved conditions are provided and can be used in whole cell vaccines to protect against pertussis or other Bordetella diseases in humans and non-human mammals.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: October 13, 2020
    Assignee: Regents of the University of Minnesota
    Inventors: Timothy Joseph Brickman, Sandra Kay Armstrong
  • Patent number: 10793602
    Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: October 6, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Steffen Walter, Jens Fritsche, Colette Song, Harpreet Singh
  • Patent number: 10781233
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular myeloma. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: September 22, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Hans-Georg Rammensee, Juliane Walz, Daniel Johannes Kowalewski, Stefan Stevanovic, Simon Walz
  • Patent number: 10765719
    Abstract: Prophylactic and/or therapeutic antipathogen agents are provided that disrupt or prevent the formation of at least one homotypic and/or heterotypic protein-protein interaction that has at least one CEA-family protein and that is involved in the establishment and colonization of a pathogen in a suitable host.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: September 8, 2020
    Inventor: Gal Markel
  • Patent number: 10766927
    Abstract: Peptides of 5 to 14 amino acids in length that stimulate subcutaneous adipogenesis and uses thereof are provided.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: September 8, 2020
    Assignee: The Regents of the University of California
    Inventors: Eva A. Turley, Seyed Bahram Bahrami, Mina J. Bissell
  • Patent number: 10766926
    Abstract: Provided are a polypeptide having the activity of inhibiting autophagy in a cell, a composition for inhibiting autophagy in a cell, and particularly in a tumor cell, containing the polypeptide as an active ingredient, and a pharmaceutical composition containing the polypeptide, and more specifically, a composition for inhibiting autophagy in a cell containing a polypeptide inhibiting the control mechanism of autophagy as an active ingredient, and a pharmaceutical composition for preventing or treating a neoplastic disease or for inhibiting resistance to anticancer agents, containing the polypeptide.
    Type: Grant
    Filed: May 28, 2018
    Date of Patent: September 8, 2020
    Assignee: L-BASE CO., LTD
    Inventors: Do Yong Jeon, Chang Hoon Moon, Ji Eun Jung
  • Patent number: 10759863
    Abstract: The present invention relate to the discovery that BTLA, IL-7 and ROR?t modulate the activity and expression of ??T cells. Specifically, the present invention provides methods of modulating ??T cell homeostasis and function by regulating expression of BTLA. The present invention further provides agents which modulate the activity and expression of BTLA, RORyt and IL-7 and methods for screening of such agents. The present invention also provides methods for treating autoimmune or inflammatory diseases using modulators of BTLA, RORyt and IL-7.
    Type: Grant
    Filed: September 4, 2014
    Date of Patent: September 1, 2020
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Carl F. Ware, John R. Sedy
  • Patent number: 10758612
    Abstract: The present disclosure relates to antibodies specific tumor associated complex N-glycans with terminal GlcNAc? residues and methods for detecting a tumor in a subject. The present disclosure also relates to therapeutic antibodies specific for tumor associated complex N-glycans with terminal GlcNAc? residues.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: September 1, 2020
    Inventor: Mai Xu
  • Patent number: 10759838
    Abstract: Disclosed is a protein comprising no more than three human autoantigenic proteins, wherein a first human autoantigenic protein comprises a truncated myelin oligodendrocyte glycoprotein (MOG) amino acid sequence, a second human autoantigenic protein comprises a myelin basic protein (MBP) amino acid sequence, and a third human autoantigenic protein comprises a truncated proteolipid protein (PLP) amino acid sequence. Also disclosed are related nucleic acids, pharmaceutical compositions, methods of treating a demyelinating disease, and methods of producing the proteins.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: September 1, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Michael J. Lenardo, Jian Li, Lixin Zheng, Jae W. Lee, Wei Lu
  • Patent number: 10753946
    Abstract: The invention relates to a novel horse allergen consisting of a heterodimeric protein having a first peptide chain and a second peptide chain together having an overall sequence identity of at least 70% with the combined sequences of SEQ ID NO:3 and SEQ ID NO: 4, as well as a single chain protein having an overall sequence identity of at least 70%, such as 75%, 80%, 85%, 90%, 95%, or 98%, with the combined amino acid sequences according to SEQ ID NO: 3 and SEQ ID NO: 4. The invention further relates to the use of the protein in methods of diagnosis and therapy of Type I allergy, and kits and compositions for use in such methods.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: August 25, 2020
    Assignee: PHADIA AB
    Inventors: Lars Mattsson, Ulrica Olsson, Thomas Lundgren, Jonas Lidholm, Håkan Larsson
  • Patent number: 10729791
    Abstract: The application relates to methods for determining a parameter such as toxicity and pharmacokinetic behavior for a pharmaceutical compound against a disease or disorder. The test animals being used are non-human animals not suffering from or is not showing symptoms or signs of the disorder and which do not provoke an immune response against said pharmaceutical compound. These animals are obtainable by administration of a peptide comprising an oxidoreductase motif further comprising an NKT peptide epitope or an MHC class II T cell epitope of said pharmaceutical compound, wherein said motif and said epitope are separated by a linker of between 0 and 4 amino acids.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: August 4, 2020
    Assignee: IMCYSE SA
    Inventors: Jean-Marie Saint-Remy, Luc Vander Elst, Vincent Carlier
  • Patent number: 10730910
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: August 4, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Juliane Walz, Daniel Johannes Kowalewski, Hans-Georg Rammensee, Stefan Stevanovic
  • Patent number: 10722555
    Abstract: The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an ?5?1 antagonist with an ?2?1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of VLO4 and VP12 (ECL12).
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: July 28, 2020
    Assignee: CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY, LLC
    Inventor: Xiaodong Feng
  • Patent number: 10717766
    Abstract: A fragment of a virulent peptide named phenol-soluble modulin (PSM) having anti-bacterial activity and methods for eliminating bacteria are provided.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: July 21, 2020
    Assignee: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
    Inventors: Meytal Landau, Asher Moshe, Nir Salinas
  • Patent number: 10718779
    Abstract: Provided are methods for determining the amount of thyroglobulin in a sample using various purification steps followed by mass spectrometry. The methods generally involve purifying thyroglobulin in a test sample, digesting thyroglobulin to form peptide T129, purifying peptide T129, ionizing peptide T129, detecting the amount of peptide T129 ion generated, and relating the amount of peptide T129 ion to the amount of thyroglobulin originally present in the sample.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: July 21, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Yanni Zhang, Nigel J. Clarke, Richard E. Reitz
  • Patent number: 10721629
    Abstract: Dynamic sharing of pooled radio access network (RAN) resources can be divided amongst different tenant carriers according to a service level agreement and/or a host carrier policy. The carriers can share the RAN with the host carrier while utilizing their own core network and service delivery platform. The hosting carrier can utilize policies to provide guidelines on how to share among the tenant carriers. Additionally, the hosting carrier can also provide services for internet-of-things devices based on security requirements with different firewall, and/or authentication requirements.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: July 21, 2020
    Assignees: AT&T Intellectual Property I, L.P., AT&T Mobility II LLC
    Inventors: Zhi Cui, Erie Lai Har Lau, Sangar Dowlatkhah
  • Patent number: 10702541
    Abstract: A composition and method for activating immune cells ex-vivo, or inducing an immune response in a subject including a composition comprising at least one chiral cationic lipid. The chiral cationic lipid in one embodiment comprises a nonsteroidal cationic lipid having a structure represented by formula (I); wherein in R1 is a quaternary ammonium group, Y1 is a spacer chosen from a hydrocarbon chain, an ester, a ketone, and a peptide, C* is a chiral carbon, R2 and R3 are independently chosen from a saturated fatty acid, an unsaturated fatty acid, an ester-linked hydrocarbon, phosphor-diesters, and combinations thereof.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: July 7, 2020
    Assignee: PDS Biotechnology Corporation
    Inventors: Elizabeth Ann Vasievich, Weihsu Claire Chen, Kenya N. Toney Johnson, Gregory Conn, Frank Bedu-Addo, Leaf Huang
  • Patent number: 10695411
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: June 30, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10675339
    Abstract: The present invention relates to methods for the recombinant expression of Chlamydia major outer membrane protein (MOMP) comprising transforming a population of E. coli host cells with an expression vector comprising a nucleic acid molecule that encodes Chlamydia MOMP and encodes a leader sequence for targeting the MOMP to the outer membrane of the cell, wherein the nucleic acid molecule is operatively linked to a promoter. The method of the invention allows expression of MOMP in the outer membrane of the cell, which leads to protein folding that is more like native MOMP relative to a MOMP protein that is expressed intracellularly. Also provided by the invention are uses of the recombinant MOMP in pharmaceutical compositions and methods for the treatment and/or prophylaxis of Chlamydia infection and/or the effects thereof.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: June 9, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Lan Zhang, Zhiyun Wen, Craig T. Przysiecki, Puneet Khandelwal
  • Patent number: 10648966
    Abstract: A conductive channel-containing membrane includes a membrane layer, and a SPP1 connector polypeptide variant that is incorporated into the membrane layer to form an aperture through which conductance can occur when an electrical potential is applied across the membrane. A method of sensing a molecule, such as a polypeptide or nucleic acid molecule, makes use of the conductive channel-containing membrane. A method of DNA sequence makes use of the conductive channel-containing membrane.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: May 12, 2020
    Assignee: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
    Inventors: Peixuan Guo, Shaoying Wang
  • Patent number: 10626174
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: April 21, 2020
    Assignee: Genentech, Inc.
    Inventors: Jane Grogan, Robert J. Johnston, Bryan Irving, Jason Hackney, Xin Yu, Dan Eaton, Kristin Bowles, Laetitia Comps-Agrar
  • Patent number: 10624934
    Abstract: Provided herein are compositions comprising a biocompatible microsphere, a biofilm-generating probiotic bacterium, a prebiotic, and/or a prebiofilmic. Methods for preparing and formulating the compositions and methods for treating or preventing a disease using the compositions are also provided.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: April 21, 2020
    Assignees: Research Institute at Nationwide Children's Hospital, Ohio State Innovation Foundation
    Inventors: Steven D. Goodman, Lauren O. Bakaletz, Michael Bailey, Gail Besner
  • Patent number: 10617748
    Abstract: The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from a tumor-associated antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the treatment of a tumor or in the treatment or prevention of a tumor relapse, and in the manufacture of medicaments therefore.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: April 14, 2020
    Assignees: LIFE SCIENCES RESEARCH PARTNERS VZW, KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventor: Jean-Marie Saint-Remy
  • Patent number: 10610574
    Abstract: Methods of treating an age-related disorder in a subject are provided. Aspects of the methods include administering to the subject a nucleic acid vector including a coding sequence for telomerase reverse transcriptase (TERT) and/or telomerase RNA (TR). Gene therapy methods are also provided. Aspects of the invention further include compositions, e.g., nucleic acid vectors and kits, etc., that find use in methods of the invention.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: April 7, 2020
    Assignee: Sierra Sciences, LLC
    Inventors: William H. Andrews, Lancer K. Brown, Hamid Mohammadpour, Laura A. Briggs
  • Patent number: 10611836
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: April 7, 2020
    Assignee: Genentech, Inc.
    Inventors: Jane Grogan, Robert J. Johnston, Bryan Irving, Jason Hackney, Xin Yu, Dan Eaton, Kristin Bowles, Laetitia Comps-Agrar
  • Patent number: 10610585
    Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: April 7, 2020
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Baylor Research Institute, Universite Paris Est Creteil Val De Marne, Assistance Publique Hopitaux de Paris
    Inventors: Yves Levy, Gerard Zurawski, Sandra Zurawski, Anne-Laure Flamar
  • Patent number: 10604570
    Abstract: The present invention relates to a chimeric antigen-receptor (CAR) signalling system comprising; (i) a targeting component comprising an antigen-binding domain, a transmembrane domain and a first heterodimerization domain; and (ii) an intracellular signalling component comprising a signalling domain and a second heterodimerization domain; wherein spontaneous heterodimerization between the first and second heterodimerization domains causes the targeting component and signalling component to form a functional CAR complex.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: March 31, 2020
    Assignee: UCL BUSINESS LTD
    Inventors: Martin Pulé, Shaun Cordoba
  • Patent number: 10590169
    Abstract: Methods and compositions for inhibiting and/or interfering with interactions between (1) programmed Death-1 protein (also known as CD279) and (2) programmed death-ligand 1 (PD-L1) and/or programmed death-ligand 2 (PD-L2) are disclosed. In addition, methods and compositions for increasing IL-2 levels in a cell, and methods and compositions for preventing, treating, or ameliorating the effects of cancer in a subject, are disclosed.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: March 17, 2020
    Assignee: Virogin Biotech Canada Ltd
    Inventors: William Jia, Xuexian Bu, I-Fang Lee
  • Patent number: RE48023
    Abstract: A method for treating a vascular-related disease in a subject in need thereof, includes administering to the subject a peptide having a sequence Xaa-Gly-Asp. The peptide may have a sequence of SEQ ID NOS: 1, 2, 4, 6 to 10. The vascular-related disease may be edema and/or ischemia caused by blood leakage of blood vessel walls, damages of blood vessels or abnormal angiogenesis.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: June 2, 2020
    Assignee: EYEGENE INC.
    Inventors: Doo-Sik Kim, Yang-Je Cho, Won-Il Yoo, Oh-Woong Kwon, Jin-Wook Jang, Hyeong-Joon Lim, Soo-Mee Kwon